| 000 | 03226cam a2200769 a 4500 | ||
|---|---|---|---|
| 999 |
_c1171 _d1171 |
||
| 001 | 99129705770001452 | ||
| 003 | MACHS | ||
| 005 | 20210413150539.0 | ||
| 008 | 921027s1993 nyu b 001 0 eng | ||
| 010 | _a 92050733 | ||
| 016 | 7 |
_a9411232 _2DNLM |
|
| 020 | _a0670841838 | ||
| 020 | _a9780670841837 | ||
| 020 |
_a1857022335 _q(FOURTH ESTATE) |
||
| 020 |
_a9781857022339 _q(FOURTH ESTATE) |
||
| 020 |
_a185702284X _q(FOURTH ESTATE1994pbk) |
||
| 020 |
_a9781857022841 _q(FOURTH ESTATE1994pbk) |
||
| 035 |
_a(OCoLC)27143771 _z(OCoLC)28692819 _z(OCoLC)59999299 _z(OCoLC)319000205 |
||
| 035 | _a(OCoLC)ocm27143771 | ||
| 035 | _a(EXLNZ-01ALLIANCE_NETWORK)99102466740001451 | ||
| 040 |
_aDLC _beng _cDLC _dVET _dMLX _dNLM _dLVB _dBAKER _dNLGGC _dBTCTA _dYDXCP _dSXC _dOCLCO _dGBVCP _dOCLCF _dUKV3G _dCN5O8 _dZJI _dOCLCQ _dALPEL _dOCLCO _dOCLCA _dOCLCQ _dTXGRD _dTXJAS |
||
| 049 | _aMAIN | ||
| 050 | 0 | 0 |
_aRC483.5.F55 _bK7 1993 |
| 060 | 0 | 0 |
_aQV 77.5 _bK89L 1993 |
| 082 | 0 | 0 |
_a616.85/27061 _220 |
| 084 |
_a44.42 _2bcl |
||
| 084 |
_a44.38 _2bcl |
||
| 100 | 1 | _aKramer, Peter D. | |
| 245 | 1 | 0 |
_aListening to Prozac / _cPeter D. Kramer. |
| 260 |
_aNew York, N.Y., U.S.A. : _bViking, _c1993. |
||
| 300 |
_axix, 409 pages ; _c24 cm |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_aunmediated _bn _2rdamedia |
||
| 338 |
_avolume _bnc _2rdacarrier |
||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aMakeover -- Compulsion -- Antidepressants -- Sensitivity -- Stress -- Risk -- Formes frustes: low self-esteem -- Formes frustes: inhibition of pleasure, sluggishness of thought -- The message in the capsule. | |
| 520 | _aKramer examines the implications of taking drugs to alter personality rather than effect illness, focusing on Prozac, a popular antidepressant. | ||
| 650 | 0 |
_aFluoxetine _xMoral and ethical aspects. |
|
| 650 | 0 |
_aFluoxetine _xSocial aspects. |
|
| 650 | 0 |
_aFluoxetine _xPsychotropic effects. |
|
| 650 | 0 | _aPersonality change. | |
| 650 | 1 | 2 |
_aFluoxetine _xpharmacology. |
| 650 | 1 | 2 |
_aFluoxetine _xtherapeutic use. |
| 650 | 2 | 2 | _aEthics, Medical. |
| 650 | 2 | 2 | _aPersonality Development. |
| 650 | 6 |
_aFluoxétine _xAspect moral. |
|
| 650 | 6 |
_aFluoxétine _xAspect social. |
|
| 650 | 6 |
_aFluoxétine _xEffets psychotropes. |
|
| 650 | 6 |
_aPersonnalité _xChangement. |
|
| 650 | 7 |
_aFluoxetine _xMoral and ethical aspects. _2fast _0(OCoLC)fst00928198 |
|
| 650 | 7 |
_aFluoxetine _xPsychotropic effects. _2fast _0(OCoLC)fst00928199 |
|
| 650 | 7 |
_aFluoxetine _xSocial aspects. _2fast _0(OCoLC)fst00928201 |
|
| 650 | 7 |
_aPersonality change. _2fast _0(OCoLC)fst01058735 |
|
| 650 | 1 | 7 |
_aFluoxetine. _2gtt |
| 650 | 1 | 7 |
_aPersoonlijkheidsontwikkeling. _2gtt |
| 650 | 7 |
_aFluoxetine _xSocial aspects. _2sears |
|
| 650 | 7 |
_aPersonality disorders. _2sears |
|
| 650 | 4 |
_aFluoxetine _xMoral and ethical aspects. |
|
| 650 | 4 |
_aPersonality change _xSocial aspects. |
|
| 653 | 0 |
_aFluoxetine _aMoral _aand _aethical _aaspects |
|
| 653 | 0 |
_aFluoxetine _aPsychotropic _aeffects |
|
| 653 | 0 |
_aFluoxetine _aSocial _aaspects |
|
| 653 | 0 |
_aPersonality _achange |
|
| 856 | 4 | 1 |
_3Table of contents _uhttp://www.gbv.de/dms/bs/toc/122420543.pdf |
| 942 |
_2lcc _cBK |
||